$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017 [Report Updated: 15-03-2017]

Published by Global Markets Direct: 15 Mar 2017 | 47500 | In Stock

Introduction

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 28, 16, 2, 32, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 19 and 8 molecules, respectively.

Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017 [Report Updated: 15-03-2017]

  • Table of Contents

    Table of Contents 2

    List of Tables 7

    List of Figures 9

    Introduction 10

    Global Markets Direct Report Coverage 10

    Congestive Heart Failure (Heart Failure) - Overview 11

    Congestive Heart Failure (Heart Failure) - Therapeutics Development 12

    Pipeline Overview 12

    Pipeline by Companies 13

    Pipeline by Universities/Institutes 19

    Products under Development by Companies 22

    Products under Development by Universities/Institutes 29

    Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 32

    Assessment by Target 32

    Assessment by Mechanism of Action 37

    Assessment by Route of Administration 42

    Assessment by Molecule Type 44

    Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 46

    Allosteros Therapeutics Inc 46

    Amgen Inc 46

    Anexon Inc 47

    AnGes MG Inc 47

    Araim Pharmaceuticals Inc 48

    Arbor Pharmaceuticals LLC 48

    Ascelegen Therapeutics Inc 49

    AstraZeneca Plc 49

    Athersys Inc 50

    Bayer AG 50

    BEAT BioTherapeutics Corp 51

    BioCardia Inc 51

    Boehringer Ingelheim GmbH 52

    Bristol-Myers Squibb Company 52

    Capricor Therapeutics Inc 53

    Celixir Ltd 53

    Celyad SA 54

    Daiichi Sankyo Company Ltd 54

    F. Hoffmann-La Roche Ltd 55

    FibroGen Inc 55

    GlaxoSmithKline Plc 56

    Heart Metabolics Ltd 56

    Hemostemix Ltd 57

    Innopharmax Inc 57

    Intrexon Corp 58

    Jiangsu Hengrui Medicine Co Ltd 58

    Juventas Therapeutics Inc 59

    La Jolla Pharmaceutical Company 59

    Lead Discovery Center GmbH 60

    Lee's Pharmaceutical Holdings Ltd 60

    Les Laboratoires Servier SAS 61

    Lonestar Heart Inc 61

    Madeleine Pharmaceuticals Inc 62

    Mast Therapeutics Inc 62

    Merck & Co Inc 63

    Mesoblast Ltd 63

    MorphoSys AG 64

    NanoCor Therapeutics Inc 64

    Neurocrine Biosciences Inc 65

    Novartis AG 65

    Nuo Therapeutics Inc 66

    Nyken BV 66

    Orion Oyj 67

    Palatin Technologies Inc 67

    PharmaIN Corp 68

    PhaseBio Pharmaceuticals Inc 68

    Quantum Genomics SA 69

    Recardio GmbH 69

    RedHill Biopharma Ltd 70

    Renova Therapeutics Inc 70

    scPharmaceuticals Inc 71

    Stealth BioTherapeutics Inc 71

    Stemedica Cell Technologies Inc 72

    Target Heart Biotec Srl 72

    Theravance Biopharma Inc 73

    TiGenix NV 73

    Torrent Pharmaceuticals Ltd 74

    Trevena Inc 74

    U.S. Stem Cell Inc 75

    Vicore Pharma AB 75

    Zensun (Shanghai) Sci & Tech Co Ltd 76

    Congestive Heart Failure (Heart Failure) - Drug Profiles 77

    (hydralazine + isosorbide dinitrate) XR - Drug Profile 77

    (sacubitril + valsartan) - Drug Profile 78

    AAVS-100A1 - Drug Profile 85

    ACP-01 - Drug Profile 87

    AdipoCell - Drug Profile 90

    AE-07 - Drug Profile 93

    AK-10 - Drug Profile 94

    aladorian sodium - Drug Profile 95

    ALD-201 - Drug Profile 97

    AMG-986 - Drug Profile 99

    AntimiR-199a - Drug Profile 100

    Antisense RNAi Gene Therapy to Inhibit ANGPTL2 for Heart Failure - Drug Profile 101

    ANX-042 - Drug Profile 102

    ARX-720 - Drug Profile 103

    AZD-4831 - Drug Profile 104

    BAY-1753011 - Drug Profile 105

    BAY-868050 - Drug Profile 106

    BBR-12 - Drug Profile 107

    beperminogene perplasmid - Drug Profile 108

    BMS-986231 - Drug Profile 114

    C-21 - Drug Profile 116

    C-Cure - Drug Profile 119

    CAP-1002 - Drug Profile 125

    Carfostin - Drug Profile 131

    carvedilol CR - Drug Profile 132

    carvedilol phosphate CR - Drug Profile 134

    Cell Therapy for Heart failure - Drug Profile 135

    cenderitide - Drug Profile 136

    cibinetide - Drug Profile 140

    CLR-325 - Drug Profile 143

    CTX-101 - Drug Profile 144

    dapagliflozin propanediol - Drug Profile 146

    Drug to Inhibit Calpain for Right Heart Failure - Drug Profile 153

    Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile 154

    ECRA-1 - Drug Profile 155

    elamipretide - Drug Profile 156

    empagliflozin - Drug Profile 164

    enalapril maleate - Drug Profile 173

    FG-6874 - Drug Profile 174

    furosemide - Drug Profile 175

    GDF-11 - Drug Profile 177

    Gene Therapy for Heart Failure - Drug Profile 178

    Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile 179

    Gene Therapy to Activate GLP-1 for Congestive Heart Failure - Drug Profile 180

    Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile 181

    Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile 182

    Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile 183

    Gene Therapy to Target mAKAPbeta for Heart Failure - Drug Profile 184

    GSK-2798745 - Drug Profile 185

    istaroxime - Drug Profile 186

    ITD-1 - Drug Profile 188

    ivabradine hydrochloride - Drug Profile 189

    ivabradine hydrochloride SR - Drug Profile 192

    JVS-100 - Drug Profile 193

    K-1062 - Drug Profile 198

    KBP-5074 - Drug Profile 199

    L-2286 - Drug Profile 201

    levosimendan - Drug Profile 202

    milrinone ER - Drug Profile 207

    Monoclonal Antibody to Activate Sodium Potassium ATPase for Congestive Heart Failure and Status Epilepticus - Drug Profile 208

    Monoclonal Antibody to Inhibit Periosti
    1 for Congestive Heart Failure - Drug Profile 209

    MP-3167 - Drug Profile 210

    MPC-150IM - Drug Profile 211

    MRS-2339 - Drug Profile 216

    MyoCell - Drug Profile 217

    MyoCell SDF-1 - Drug Profile 219

    NBI-69734 - Drug Profile 220

    neladenoson bialanate - Drug Profile 221

    Neucardin - Drug Profile 222

    NM-922 - Drug Profile 225

    NP-202 - Drug Profile 226

    NPA-7 - Drug Profile 228

    NYK-1112 - Drug Profile 229

    Oligonucleotides to Antagonise Beta 1 Adrenergic Receptor for Pediatric Heart Failure - Drug Profile 230

    omecamtiv mecarbil MR - Drug Profile 231

    PB-1046 - Drug Profile 239

    Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile 241

    Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile 242

    perhexiline maleate - Drug Profile 243

    PF-05285401 - Drug Profile 245

    PHIN-1138 - Drug Profile 257

    pirfenidone - Drug Profile 258

    PL-3994 - Drug Profile 265

    PL-5028 - Drug Profile 267

    poloxamer - Drug Profile 268

    pyroglutaminated serpinin - Drug Profile 270

    QGC-101 - Drug Profile 271

    REC-02 - Drug Profile 272

    Recombinant Protein for Congestive Heart Failure - Drug Profile 273

    ROMKi-B - Drug Profile 274

    RT-100 - Drug Profile 275

    RT-110 - Drug Profile 277

    RT-300 - Drug Profile 278

    RT-400 - Drug Profile 279

    S-38844 - Drug Profile 280

    serelaxin - Drug Profile 281

    serpinin - Drug Profile 286

    SG-1002 - Drug Profile 287

    Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 288

    Small Molecule to Inhibit CYP11B2 for Heart Failure - Drug Profile 289

    Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 290

    Small Molecules for Diastolic Heart Failure - Drug Profile 291

    Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 292

    Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 293

    Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 294

    Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 295

    Small Molecules to Inhibit GRK2 for Heart Failure - Drug Profile 296

    Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 297

    Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 298

    Small molecules to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure, Breast Cancer and Chronic Obstructive Pulmonary Disease - Drug Profile 299

    Small Molecules to Inhibit Porcupine for Oncology, Degenerative Disorders And Congestive Heart Failure - Drug Profile 300

    Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 301

    Small Molecules to Target Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 302

    sodium nitrite - Drug Profile 303

    SP-20202 - Drug Profile 307

    Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 308

    Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 314

    Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile 315

    Stem Cell Therapy for Heart Failure - Drug Profile 316

    Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 317

    Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 318

    Synthetic Peptide to Agonize Beta 2 Adrenergic Receptor for Congestive Heart Failure - Drug Profile 319

    Synthetic Peptide to Agonize Guanylate Cyclase A for Cardiovascular Disorders - Drug Profile 320

    TD-0714 - Drug Profile 321

    TD-1439 - Drug Profile 323

    TR-4 - Drug Profile 324

    TRC-4186 - Drug Profile 325

    TRV-120023 - Drug Profile 327

    ularitide - Drug Profile 328

    valsartan CR - Drug Profile 330

    VCP-746 - Drug Profile 331

    vericiguat - Drug Profile 332

    Xcel-hCardP - Drug Profile 334

    Congestive Heart Failure (Heart Failure) - Dormant Projects 335

    Congestive Heart Failure (Heart Failure) - Discontinued Products 341

    Congestive Heart Failure (Heart Failure) - Product Development Milestones 343

    Featured News & Press Releases 343

    Appendix 354

    Methodology 354

    Coverage 354

    Secondary Research 354

    Primary Research 354

    Expert Panel Validation 354

    Contact Us 354

    Disclaimer 355

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

47500 | GMDHC9049IDB

Number of Pages

364

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Congestive Heart Failure Partnering 2010 to 2017
The Global Congestive Heart Failure Partnering since 2010 report provides understanding and access t...
01 Feb 2017 by Current Partnering USD $1,495 More Info
Global Congestive Heart Failure Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Congestive Heart Failure Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2016
Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2016SummaryGlobalData's ...
31 Mar 2016 by Global Data USD $2,500 More Info
Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2016
Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2016SummaryGlobalData's ...
31 Mar 2016 by Global Data USD $2,500 More Info
Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H2, 2015
Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H2, 2015SummaryGlobalData's ...
23 Dec 2015 by Global Data USD $2,500 More Info
Congestive Heart Failure - Pipeline Analysis
“Congestive Heart Failure (CHF) Pipeline Analysis” gives comprehensive insight on the various drugs ...
07 May 2015 by IQ4I USD $3,600 More Info
Congestive Heart Failure - Pipeline Analysis
“Congestive Heart Failure (CHF) Pipeline Analysis” gives comprehensive insight on the various drugs ...
07 May 2015 by IQ4I USD $3,600 More Info
Congestive Heart Failure - Pipeline Analysis
“Congestive Heart Failure (CHF) Pipeline Analysis” gives comprehensive insight on the various drugs ...
07 May 2015 by IQ4I USD $3,600 More Info
Congestive Heart Failure - Pipeline Analysis
“Congestive Heart Failure (CHF) Pipeline Analysis” gives comprehensive insight on the various drugs ...
07 May 2015 by IQ4I USD $3,600 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017 [Report Updated: 15-03-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data